Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown [1] [2] [3] [4] [5] [6] [7] [8] [9] . Here, by annotating the landscape of FOXA1 mutations from 3,086 human prostate cancers, we define two hotspots in the forkhead domain: Wing2 (around 50% of all mutations) and the highly conserved DNA-contact residue R219 (around 5% of all mutations). Wing2 mutations are detected in adenocarcinomas at all stages, whereas R219 mutations are enriched in metastatic tumours with neuroendocrine histology. Interrogation of the biological properties of wild-type FOXA1 and fourteen FOXA1 mutants reveals gain of function in mouse prostate organoid proliferation assays. Twelve of these mutants, as well as wild-type FOXA1, promoted an exaggerated pro-luminal differentiation program, whereas two different R219 mutants blocked luminal differentiation and activated a mesenchymal and neuroendocrine transcriptional program. Assay for transposase-accessible chromatin using sequencing (ATAC-seq) of wild-type FOXA1 and representative Wing2 and R219 mutants revealed marked, mutant-specific changes in open chromatin at thousands of genomic loci and exposed sites of FOXA1 binding and associated increases in gene expression. Of note, ATAC-seq peaks in cells expressing R219 mutants lacked the canonical core FOXA1-binding motifs (GTAAAC/T) but were enriched for a related, non-canonical motif (GTAAAG/A), which was preferentially activated by R219-mutant FOXA1 in reporter assays. Thus, FOXA1 mutations alter its pioneering function and perturb normal luminal epithelial differentiation programs, providing further support for the role of lineage plasticity in cancer progression.
Letter reSeArCH F266), some of which are predicted to be sites of direct DNA contact 10 ( Fig. 1a, Extended Data Fig. 1 ). Another mutational hotspot is at R219, a DNA-contact site in α-helix 3, which is a highly conserved fold of the FKHD domain that sits in the major groove of target DNA (Extended Data Fig. 1 ). Finally, 20% of FOXA1 mutations encode truncations just downstream of the FKHD DNA-binding domain, resulting in the loss of the C-terminal transactivating domain. Annotation of all FOXA1 mutations in the MSK-IMPACT 504 cohort 11 revealed that Wing2-hotspot mutations-the most common subclass-are found across all disease stages, but are more prevalent in primary locoregional cases (Fig. 1c) . There are only four cases of R219 mutation in FOXA1 in this cohort but, notably, two of these had castration-resistant disease. We therefore expanded the analysis to 1,822 patients by including a larger cohort from MSK-IMPACT and a published cohort from Weill Cornell 12 , which is enriched for neuroendocrine prostate cancer (NEPC), and observed significant enrichment (P < 0.006) of R219 mutations versus other FOXA1 mutations in NEPC (3 out of 4) versus adenocarcinoma (8 out of 84) (Fig. 1d) .
We next investigated whether FOXA1 mutation in patients is associated with clinical outcome. In the absence of appropriate longitudinal c, Overexpression of wild-type (+WT) or various FOXA1 mutants promotes growth ten days after seeding in medium lacking EGF. d, Quantification of lumen-containing organoids for each line in the Foxa1 allelic series. All values of P are relative to empty vector control, calculated using unpaired, two-tailed Student's t-test. e, Histology and immunohistochemistry of organoid lines overexpressing variants of FOXA1 via the doxycycline-inducible pCW vector ten days after seeding.
Images from a single biological experiment. H&E, haematoxylin and eosin staining. Scale bars: top, 200 μm; other rows, 100 μm. f, Summary of GSEA comparing Foxa1 wild-type or mutant organoid lines to empty vector control for a basal low (luminal) gene set, the hallmark EMT gene set and a gene set of the top 100 genes induced following ERF knockdown (using short hairpin RNA directed against ERF, shERF) in organoids. Data are from RNA-sequencing (RNA-seq) analysis of three biological replicates for each organoid line. Only comparisons with an FDR of <0.25 are shown with the corresponding normalized enrichment score. Gene sets with a positive normalized enrichment score are enriched in organoids that have either Foxa1 wild-type or mutant alleles. Data in a-d are mean ± s.d. Numbers of biological replicates (indicated as dots) and specific P values are presented in the source data. *P < 0.05, **P < 0.01, NS, not significant. All P values are relative to overexpression of wild-type FOXA1 unless otherwise noted; unpaired, two-tailed Student's t-test.
Letter reSeArCH data, we generated an RNA signature using mutant FOXA1 status of The Cancer Genome Atlas (TCGA) samples to interrogate the Decipher GRID cohort of 1,626 primary prostate cancer patients 13 and found that tumours predicted to be FOXA1 mutant were significantly associated with higher Gleason Scores, shorter time to biochemical recurrence and more rapid progression to metastatic disease than unaltered cases (Extended Data Fig. 1b, c) . Together with recent evidence 14 , these data suggest that patients with FOXA1 mutations have a less favourable prognosis.
To characterize a large panel of the most recurrent alterations seen in prostate cancer, including truncating mutations, we generated a FOXA1 reporter construct (Extended Data Fig. 2) , and found that all Wing2 mutations, D226N (a mutation in spatial proximity to Wing2 in the protein 10 ) and the truncation mutant G275X result in increased transcriptional activity (around twofold) compared to the wild type, whereas mutations at R219 (R219S and R219C) cause impaired activity (around 50% of wild-type activity) (Fig. 2a) . To investigate the consequences of FOXA1 mutations on the growth of prostate cells, we used primary mouse prostate organoid culture (previously used to model tumour initiation) 15 by introducing a series of wild-type or mutant mouse Foxa1 alleles using doxycycline-inducible lentiviral constructs (Extended Data Fig. 3a-c) . Increased expression of wild-type (WT) FOXA1 resulted in a 2-3-fold increase in growth compared to vector control. This relative difference was substantially greater (about 50-fold) after removal of epidermal growth factor (EGF), a critical growth factor for normal organoid proliferation (Fig. 2b) . In this setting, nearly all mutants tested showed an increase in growth relative to overexpression of FOXA1(WT), including the two α-helix 3 mutants (R219S and R219C) that had reduced reporter activity, as well as the truncation mutant G275X (Fig. 2c) . All 14 mutants promoted growth relative to the empty vector control.
We next examined the histological features of the resulting organoids. We observed that increased expression of FOXA1(WT), FOXA1(D226N) or the Wing2-hotspot mutations all promote exaggerated lumen formation and size (Fig. 2d, e, Extended Data Fig. 3d ). By contrast, organoids expressing FOXA1(R219S), and to a lesser extent those expressing FOXA1(R219C), were unable to form measurable lumens, and the bilayer orientation of basal (p63 + ) and luminal (androgen receptor-positive (AR + )) cell layers appeared disrupted (Fig. 2e, Extended Data Fig. 3e ). This phenotype resembles that of FOXA1-deficient organoids generated using CRISPR-Cas9 (Extended Data Fig. 4a-c) , consistent with mouse models 16 . We also repeated the overexpression studies in endogenous-Foxa1-deleted organoids using CRISPR-resistant cDNAs encoding two pro-luminal FOXA1 mutants (ΔF254/E255 and D226N) and found that the pro-luminal phenotype was unchanged (Extended Data Fig. 4d-g ). Findings from RNA sequencing were consistent with these histologies. Mutants conferring a pro-luminal phenotype showed similarity to ETS-mutant luminal organoids 17 by gene-set enrichment analysis (GSEA), with the notable exception of FOXA1(R219S), which instead showed enrichment of an epithelial-mesenchymal-transition (EMT) program and a repression of the ETS-mutant gene set (Fig. 2f) , consistent with Letter reSeArCH its distinct morphology. We also examined the activity of FOXA1 in an in vivo setting 18, 19 and observed increased proliferation across all lines, an increase in subcutaneous tumour size in two of four lines (FOXA1(WT) and FOXA1(G275X)), and an increased prevalence of invasive, intraductal basal disease (defined by the loss of AR expression) in tumours derived from FOXA1(R219S) organoids transduced with single-guide RNA (sgRNA) directed against PTEN-consistent with FOXA1(R219S) histology in vitro (Extended Data Fig. 4h-j) .
As FOXA1 is a cofactor for AR and FOXA1 mutant cases in the TCGA cohort have higher AR scores than either normal samples or other subtypes 6 , we examined the AR cistrome. The number of AR binding peaks (defined by AR chromatin immunoprecipitation with sequencing (ChIP-seq)) is markedly reduced in organoids overexpressing wild-type or mutant FOXA1 (Fig. 3a, left, Extended Data  Fig. 6a ). However, FOXA1 binding is enhanced at the sites where AR binding is lost (Fig. 3a , right, P < 1 ×10 −300
, Extended Data Fig. 5a ). for expression of wild-type or mutant FOXA1 relative to empty vector. Right, includes counts for organoids following CRISPR-mediated Foxa1 deletion five days after trypsinization, relative to the control sgRNA. Data are from three biological replicates, with FDR <0.05 using two-sided Wald test, with Benjamini-Hochberg FDR correction for multiple observations. b, ATAC-seq peak heat maps comparing organoids with (sgFoxa1_1, sgFoxa1_2) or without (sgNT) CRISPR-mediated deletion of Foxa1 or expression of wild-type or mutant FOXA1 after five days of doxycycline treatment, with eight clusters defined by hierarchical clustering. c, FOXA1 ChIP-seq signal at genomic loci matching ATAC-seq clusters defined in b shows a similar pattern of peaks correlating FOXA1 binding with open chromatin. Data are from two biological replicates. d, Enrichment or depletion of FOXA1 motif variants in clusters that gain accessibility in organoids overexpressing FOXA1(ΔF254/E255) or FOXA1(R219S), including the canonical motif, divergent and convergent dimer motifs, and altered versions of the FOXA1 motif (GTAAAY, similar to canonical, and GTAAAR, non-canonical), expressed as a binomial Z-score computed from the number of cluster peaks with >1 motif occurrence relative to background occurrence in all heat map peaks. Occurrence within a given cluster is reported in the bar graph. Positive scores indicate enrichment; negative scores indicate depletion. e, Luciferase reporter assay showing activity of FOXA1 variants on GTAAAY (blue) or GTAAAR (red) DNA templates. Luciferase (ratio over Renilla luciferase signal, see Methods) signal normalized to signal from FOXA1(WT) on GTAAAY reporter. Data are from three biological replicates, mean ± s.d. Unpaired, twotailed Student's t-test. No significant difference between activity of wild type and R219S on the GTAAAR reporter (P = 0.2314). FOXA1(ΔF254/ E255) has significantly less activity on GTAAAR than either FOXA1(WT) (P = 0.0059) or FOXA1(R219S) (P = 0.0033).
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This suggests that FOXA1 may replace AR function at these sites, supported by retention of the increased growth advantage conferred by FOXA1 despite CRISPR-mediated deletion of Ar (Fig. 3b, Extended  Data Fig. 5b ). To reconcile the high AR scores seen in TCGA with this AR-independent growth program, we examined expression levels of the mouse orthologues of the human AR gene signature 20 and found that the majority are induced by FOXA1 (Extended Data Fig. 5c ). Thus, while the number of AR-binding sites is substantially reduced, a core set of AR-target genes are maintained in the setting of increased FOXA1 activity. We also investigated whether transcriptomic changes observed in the Foxa1 mutant mouse organoids were similar to those observed in FOXA1 mutant human tumours. Remarkably, the human orthologues of differentially expressed genes in FOXA1(ΔF254/E255) mouse organoids were sufficient to cluster FOXA1 mutant tumours within the TCGA cohort (P = 2.1 × 10 −8
, Extended Data Fig. 5d ). Given the role of FOXA1 as a pioneer transcription factor, we conducted a genome-wide analysis of changes in open and closed chromatin using ATAC-seq. Expression of FOXA1(WT) led to an increase in open chromatin after five days (more than 1,000 open peaks with significant change in accessibility, false discovery rate (FDR) < 0.05, log fold change of 2 in peak read coverage compared to control) whereas deletion of Foxa1 led to the opposite, with the closing of around 1,000 peaks. Organoids expressing FOXA1(ΔF254/E255) and FOXA1(R219S) also had increased peak numbers, but these changes occurred substantially faster (in one day) and involved many more peaks (Fig. 4a) , consistent with altered pioneering activity.
Unsupervised clustering analysis identified distinct sets of peaks for FOXA1(ΔF254/E255) and FOXA1(R219S) (Fig. 4b) . Cluster 0 is largely defined by marked peak changes observed with both FOXA1(WT) and FOXA1(ΔF254/E255), demonstrating that overexpression of wildtype FOXA1 opens new regions of chromatin compared with controls; this effect is amplified in cells expressing FOXA1(ΔF254/E255). By contrast, organoids expressing FOXA1(R219S) gain thousands of distinct peaks (defined by clusters 3 and 5) without changes in cluster 0. ChIPseq reveals that FOXA1 protein binds at these same ATAC-seq loci (Fig. 4c, Extended Data Fig. 6a-d ) and cumulative distributive function plots confirm that there are mutation-specific changes in expression of the genes that map to these newly open chromatin peaks (Extended Data Fig. 6e-h ).
Motif analysis revealed enrichment of FOXA1-binding motifs in clusters 0 and 1 (FOXA1(WT) and FOXA1(ΔF254/E255)) (Extended Data Fig. 7a ) but not in clusters 3 and 5 (FOXA1(R219S)), despite evidence of FOXA1(R219S)-DNA binding and associated geneexpression changes. However, de novo motif analysis of cluster 3 peaks identified a motif with similarities to the core GTAAA(C/T) FOXA1 binding motif but with substitution of (G/A) for (C/T) at position 6 (Extended Data Fig. 7b ). This impression was confirmed by selective enrichment of the (G/A) motif in clusters 3 and 5 versus the (C/T) motif in clusters 0 and 1 (Fig. 4d) . To determine whether this motif is functional, we repeated the reporter assays described in Fig. 2a with FOXA1(R219S) and found that FOXA1(R219S) preferentially activates a DNA template modified to reflect the (G/A) bias at position 6, whereas FOXA1(WT) and FOXA1(ΔF254/E255) exhibit substantially higher activity on the canonical (C/T) sequence (Fig. 4e , Extended Data Fig. 7c-e) , suggesting a mechanism by which FOXA1(R219S) selectively targets novel genomic loci. Finally, two motifs recently associated with FOXA1 dimers-termed convergent and divergent 21 -were relatively enriched in cluster 0 versus cluster 1, potentially explaining the novel pioneering activity of FOXA1(ΔF254/E255) (Fig. 4d) .
Collectively, our analysis of mutant FOXA1 alleles in prostate cancer reveals unanticipated and diverse consequences for the pioneering function of FOXA1. Wing2 mutants display a gain in pioneering activity that is substantially greater than that observed by overexpression of comparable levels of FOXA1(WT), but both alterations affect nearly identical regions of the genome (cluster 0) that are distinguishable from endogenous FOXA1 sites (cluster 1) on the basis of enrichment of FOXA1 dimer motifs. We postulate that the changes in gene expression associated with these novel open regions contribute to oncogenesis. By contrast, FOXA1 R219 mutants display pioneering function over distinct regions of the genome (clusters 3 and 5) enriched for a variant FOXA1-binding motif that, on the basis of reporter assays, is permissive for the binding of FOXA1 R219 mutants despite mutation of the α-helix 3 consensus DNA-binding residue. Further investigation of the relative DNA-binding affinities of these mutants for the different motifs and the potential role of the Wing2 domain in this retained DNA binding (based on known DNA contacts in the minor groove) is warranted. In both classes of mutations, the biological consequence is lineage plasticity for pro-luminal versus anti-luminal programs.
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Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized. For all assays except lumen area quantification and histological assessment of xenograft tumors, the investigators were not blinded to allocation during experiments and outcome assessment. Pan-prostate cancer mutation analysis. The 12 cohorts used for analysis (total of 3,086 samples) included published datasets as well as unpublished data from the MSK-IMPACT 1708 cohort (frozen 25 May 2018), across all stages of prostate cancer (see Supplementary Table 1 ). Samples were compiled and duplicate samples were pruned to generate a master list of 3,086 prostate cancer cases, which were then stratified on the basis of their FOXA1 alteration status and the class of mutation in the samples. The Wing2 hotspot includes cases with mutations or indels between H247 and E269. Truncations after the FKHD domain were defined as any frameshift alteration distal to residue E269. Any mutation that did not specifically fall into one of the distinct classes was called 'other' . Sample analysis was performed in part using the CBioPortal for Cancer Genomics 22, 23 . 3D modelling. Three-dimensional representation of the FKHD domain of FOXA3 complexed with DNA was generated using PyMOL (PDB: 1VTN). Constructs. To create pCW-Flag-2A-dsRED (pCW-EV), sequences for p2A and DsRED were cloned in the pCW-Cas9 plasmid (Addgene Plasmid #50661) using in-fusion cloning (Takara Bio). To generate pCW-Flag-Foxa1-2A-dsRED (pCWFoxa1), mouse Foxa1 cDNA was cloned into pCW-Flag-2A-dsRED using in-fusion cloning (Takara Bio). All primers and sequences are listed in Supplementary  Table 2 . To generate the sgRNA vector CRISPR-Zeo, GFP from pLKO5.sgRNA. EFS.GFP (a gift from B. Ebert, Addgene plasmid no. 57822) was excised with BamHI and MluI. The zeomycin-resistance gene was removed from lenti sgR-NA(MS2)_zeo backbone (a gift from F. Zhang, Addgene plasmid no. 61427) using BsrGI and EcoRI. ZeoR was ligated into the pLKO5.sgRNA.EFS backbone in a four-way ligation using BamHI-BsrGI and EcoRI-MluI adaptors. To create the LVX-UbC-EGFP-Luc2_Hygro construct for visualization of injected cells by live imaging or immunohistochemistry, we first generated the plasmid LVX-UbC-EGFP-Luc2_Puro as follows: 0.72 kb EGFP cDNA from pQCXIP-EGFP 24 was cloned into the BamHI and NotI sites of pLVX-TRE3G-IRES (Clontech, 631362) via a EcoRI-NotI cloning adaptor to make pLVX-TRE3G-EGFP-IRES. The TRE3G promoter was then removed with an XhoI and BamHI digestion, and replaced with the 1.26-kb UbC promoter obtained from Duet011 (Addgene) with a PacI and BamHI digest and using a XhoI-PacI cloning adaptor to make pLVXUbC-EGFP-IRES. pLVX-UbC-EGFP-Luc2 was then constructed by cloning the 1.7 kb-Luc2 cDNA derived from pGL4.10(luc2) (Promega) with a HindIII and XbaI digest into the MluI and EcoRI sites of pLVX-UbC-EGFP-IRES via MluI-HindIII and XbaI-EcoRI cloning adaptors. The puromycin cassette was replaced with the hygromycin cassette to generate LVX-UbC-EGFP-Luc2_Hygro. Generation of FOXA1 mutant cDNA. Site directed mutagenesis was carried out on pCW-Flag-Foxa1-2A-dsRED to induce patient mutations in the cDNA using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent), according to the manufacturer's protocol. Primers were designed using Agilent's QuikChange Primer Design tool (https://www.genomics.agilent.com/primerDesignProgram. jsp). To prevent CRISPR-Cas9 targeting by sgFOXA1_1 sgRNA mutagenesis was used to introduce three silent mutations in the sgRNA recognition sequence (see Extended Data Fig. 8a ). Guide RNA design. Guide RNAs targeting mouse Foxa1, Ar and Pten were generated using the CRISPR design tool (http://crispr.mit.edu). sgFoxa1_1 targets the cDNA near the 5′ end, whereas sg_Foxa14 and sgFoxa1_15 target the FKHD DNAbinding domain. Control guides sgNT (targeting safe harbour locus AAVS1 25 ) and sgGFP were used. All guide RNAs were cloned into lentiCRISPRv2 (Addgene no. 52961), lentiGuide-Puro (Addgene no. 52963) or CRISPR-Zeo using BsmbI digest, according to the Zhang laboratory protocol. For cells carrying CRISPR-Zeo or lentiGuide-Puro, lentiCas9-Blast (a gift from F. Zhang, Addgene plasmid no. 52962) was used as the Cas9 source. FOXA1 luciferase reporter pGL-6xFBS-Luc. Oligonucleotide fragments containing six tandem FKHD-consensus (canonical or non-canonical) motifs with 5-bp spacers (Supplementary Table 2 ) were cloned into pGL4.28 luc2CP/minP/hygro (Pomega) between HindIII and XhoI restriction sites. Oligonucleotide sequences were verified using Sanger sequencing. Canonical FOXA1-binding sites were based on the top binding motifs predicted on the basis of ChIP-seq results in HepG2 cells 26 , whereas the non-canonical FOXA1-binding site was based on the top hit of de novo motif analysis of ATAC-seq cluster 3 using HOMER (Extended Data Fig. 10 ). The pGL-5xFBS-Luc was transiently transfected using Lipofectamine 2000 (Thermo Fisher) into lentiX293T cells (Clonetech) along with CMV-Renilla (pRL-CMV Renilla, Promega) as an internal control. Response ratios are expressed relative to signal obtained for the positive-control wells transfected with 170 ng of pCMV6-mFOXA1mycDDK (Origene MR225487), which was set to 1, and the negative-control well receiving 170 ng of 'stuffer' DNA (pCW-Flag-2A-dsRED (pCW-EV), no exogenous FOXA1), which was set to 0. To test the response of these reporters to varying levels of FOXA1 introduced into the system, ratios of pCMV6-mFOXA1mycDDK and pCW-EV constructs were altered, keeping the total amount of DNA transfected into each well constant. In evaluating the relative response ratios between FOXA1(WT) and various mutants, one concentration of cDNA (170 ng per well) was used and relative response ratios reflect activity of given variant on the reporter. Luminescence measurements were taken 24 h after transfection. All results are means and standard deviations from experiments performed in biological triplicates (as a minimum, n ranging from 3 to 7) (see source data for Fig. 2 for details), and Firefly luciferase activity of individual wells was normalized against Renilla luciferase activity. Organoid lines. All parental organoid lines were established in our laboratory as previously described 15 . The blue red organoids (BRO) line was established from mice harbouring red fluorescent protein (RFP) driven by a composite human keratin 18 promoter and cerulean fluorescent protein (CFP) driven by a bovine keratin 5 promoter
27
. BROs were transduced with lentiCrisprv2 carrying either sgNT or sgFoxa1_1 and selected using puromycin. BRO lines were maintained in standard mouse organoid media conditions 15 . K14-1 organoids were derived from mice harbouring an actin-GFP fusion protein driven by a human keratin 14 promoter 28 . K14-1 organoids were transduced with the allelic series of pCW-Foxa1 wild-type or mutant constructs, as well as pCW-EV as a control. Bulk cells were selected using puromycin. K14-1 organoids were maintained in standard mouse organoid media conditions 15 , with 2.5 ng/ml EGF supplementation. For rescue experiments of either Foxa1 or Ar deletion, K14-1 organoids carrying pCW-Foxa1 constructs were subsequently transduced with lentiCas9-Blast, bulk selected with blasticidin, and then transduced with either CRISPR-Zeo-sgFoxa1_1 or sgGFP, or sgAr and bulk selected with zeocin. Rosa26-Cas9-sgPTEN-luc2-pCW-FOXA1 organoids were derived from a homozygous Rosa26 Lox-stop-Lox Cas9 mouse (C67BL/6J background, Jackson Laboratory 026175) and transduced with adenoCre-GFP in vitro for expression of Cas9. These cells were then transduced with lentiGuidePuro-sgPten and bulk selected with puromycin, transduced with LVX-UbC-EGFPLuc2_Hygro and bulk selected with hygromycin, transduced with the allelic series of pCW-Foxa1 wild-type or mutant constructs or pCW-ERG, as well as pCW-EV as a control, and sorted for dsRED expression to enrich for transduced cells. Organoid culture. Mouse organoids were sorted, cultured in 3D and transduced with lentiviruses as described previously 15, 29 . Organoids infected with pCW-EV, pCW-FOXA1, or LentiCrispV2 constructs were selected with 2 μg/ml puromycin for 5 days, 3-4 days after transduction, while those infected with CRISPR-Zeo were selected with 30 μg/ml for 7 days, 3-4 days after transduction. Transduction with Lenti-Cas9-Blast was followed by five days of selection in 10 μg/ml blasticidin. Preparation of 3D organoids for histology was carried out as previously described 15 .
Haematoxylin and eosin staining and immunohistochemistry was carried out by the MSKCC Molecular Cytology Core. Cells were confirmed to be free of mycoplasma using the Lonza MycoAlert Mycoplasma Detection Kit (LT07-318). Growth assays. Organoids were treated with doxycycline (500 ng/ml) to induce expression of the FOXA1-2A-DsRED fusion, then sorted two days later to enrich for DsRED + cells. Cells were seeded at a density of 100 cells per μl (2,000 cells per 20-μl dome, three domes per line per time point, each dome in a single well of a 48-well plate) and maintained on doxycycline for the duration of the assay, refreshing media every 2-3 days. Y-27632 was supplemented for the first feeding at 10 μM. To measure proliferation, matrigel domes were washed with PBS, and then resuspended in 100 μl of PBS, and CellTiter-Glo 2.0 Assay (Promega) was used, following the manufacturer's instructions. Triplicate values for each time point were averaged, and all values on subsequent days were normalized to the day 1 reading. Experiments were repeated at least three times independently and each line was normalized to the empty vector control readings for a given replicate. Lumen formation assays. Organoids were treated with doxycycline (500 ng/ml) to induce expression of the FOXA1-2A-DsRED fusion. Doxycycline-treated cells were sorted two days later to enrich for DsRED + cells. Sorted cells were seeded in matrigel at a density of 3 cells per μl (eight 25-μl domes per organoid line) and maintained on doxycycline for the duration of the assay, with fresh medium every 2-3 days. Y-27632 was supplemented for the first feeding at 10 μM. After 10 days, organoids were scored for the presence or absence of a visible lumen by bright-field microscopy, and the percentage of the total number of organoids that possessed a lumen was determined from examining ~50-200 organoids in a typical experiment. In CRISPR organoid lines, sorting was not performed for the lumen formation assay. Instead cells were trypsinized to a single-cell suspension, counted using trypan blue exclusion, and then seeded as described above. Experiments were repeated three times independently. Lumen area measurements. Organoids were treated with doxycycline (500 ng/ml) to induce expression of the FOXA1-2A-DsRED fusion. Doxycycline-treated cells were sorted two days later to enrich for DsRED + cells. Sorted cells were seeded in matrigel in a dilution series of densities ranging from 32 cells per μl down to 4 cells per μl (five domes per density per line) and maintained on doxycycline for the duration of the assay, with the medium refreshed every 2-3 days. Y-27632 was Letter reSeArCH supplemented for the first feeding at 10 μM. After 10 days, the area of each visible lumen was measured using light microscopy and Nikon NIS Elements software. In a typical experiment, ~30-50 organoids were measured by an observer blinded to organoid genotypes. Western blot. Membranes were probed with antibodies directed against AR (1:1,000, ER179(2), Abcam), FOXA1 (1:1,000, Ab2, Sigma), cyclophilin B (1:1,000, EPR12703(B), Abcam), Flag (1:1,000, M2, Sigma) or PTEN (1:1,000, D4.3, Cell Signaling). Signal was visualized with secondary HRP-conjugated antibodies and chemiluminescent detection. Immunohistochemistry. Organoids and tumours were processed and stained as described previously 15 . The following antibodies were used for staining on mouse organoids and organoid-derived xenografts: HNF-3-α/FOXA1 antibody (5 μg/ml, 3B3NB, Novus Biologicals), AR (1:1,000, N-20, Santa Cruz), p63 (1:800, 4A4, Ventana). Staining was visualized with BrightVision (Dako), Ki67 (Abcam ab15580 at 1 μg/ml). In vivo experiments. In vivo xenograft experiments were performed by subcutaneous injection of 2 × 10 6 dissociated organoid cells (Rosa26-Cas9-sgPTEN-luc2-pCW-FOXA1 or ERG) resuspended in 100 μl of 50% matrigel (BD Biosciences) and 50% growth medium into the flanks of five 8-to-12-week-old male NOD. Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (005557, The Jackson Laboratory) to yield ten tumours per group. As soon as palpable, tumour volume was measured weekly using the tumour-measuring system Peira TM900 (Peira). Tumours were then collected at given time points for histology using 4% paraformaldehyde. Histological assessment was carried out by an observer blinded to tumour genotypes. All animal experiments were performed in compliance with the guidelines of the Research Animal Resource Center of the Memorial Sloan Kettering Cancer Center. In accordance with our IACUC and our approved protocol, none of the mice exceeded the maximum tumour burden allowed (total for both sides) of 2,000 mm 3 . RNA isolation and sequencing. RNA was extracted from organoids using an RNeasy Kit (Qiagen). Freshly sorted dsRED + cells were seeded in triplicate per infected construct at the start of the assay, and moving forward, replicates were processed independently, collected at the appropriate time points. Library preparation and sequencing were performed by the New York Genome Center, where RNA-seq libraries were prepared using the TruSeq Stranded mRNA Library Preparation Kit (Illumina) in accordance with the manufacturer's instructions. In brief, 100 ng of total RNA was used for purification and fragmentation of mRNA. Purified mRNA underwent first and second strand cDNA synthesis. cDNA was then adenylated, ligated to Illumina sequencing adapters, and amplified by PCR (using 10 cycles). Final libraries were evaluated using fluorescent-based assays including PicoGreen (Life Technologies) or Qubit Fluorometer (Invitrogen) and Fragment Analyzer (Advanced Analytics) or BioAnalyzer (Agilent 2100), and were sequenced on an Illumina HiSeq2500 sequencer (v.4 chemistry, v.2 chemistry for Rapid Run) using 2 × 50-bp cycles. Reads were aligned to the mm10 mouse reference genome using STARaligner 30 (v.2.4.2a). Quantification of genes annotated in Gencode vM2 was performed using featureCounts (v.1.4.3) and transcripts were quantified using Kalisto 31 . Quality control statistics were collected with Picard (v.1.83) and RSeQC 32 (http://broadinstitute.github.io/picard/). Normalization of feature counts was done using the DESeq2 package 33 . Analysis of RNA-seq from mouse organoids and patient samples. The gene read count data of TCGA primary prostate cancer were downloaded using the GDC tool. The mouse and human homologous genes were downloaded from Mouse Genome Informatics from The Jackson Laboratory (http://www.informatics.jax. org/homology.shtml). Differential expression analyses were performed using DESeq2 (https://bioconductor.org/packages/release/bioc/html/DESeq2.html) based on the gene read count data. Multiple-hypothesis testing was considered by using Benjamini-Hochberg correction. The statistical significance of the overlap between two groups of genes was tested using Fisher's exact test. GSEA was performed using the JAVA program (http://www.broadinstitute.org/gsea) and run in pre-ranked mode to identify enriched signatures. The GSEA plot, normalized enrichment score and FDR and q values were derived from GSEA output. The following gene sets were used: Hallmark gene sets, Neuroendocrine high 12 , Basal low 34 , and shERF up 17 . Prostate cancer tumour samples and microarray data. A total of 1,959 radical prostatectomy tumour expression profiles were used for training and testing. For training and testing, we used RNA-seq expression and DNA mutation data from TCGA prostate cancer project 6 (n = 333). For testing, the expression profiles of retrospective (n = 1,626) were derived from the Decipher GRID registry (NCT02609269 (TJU) . Associated accession numbers are: GSE79957, GSE72291, GSE62667, GSE62116, GSE46691, GSE41408, and GSE21032. DNA and RNA from the TCGA cohort were extracted from fresh frozen radical prostatectomy tumour tissue, as previously described 6 . RNA from the GRID cohorts was extracted from routine formalin-fixed, paraffin embedded (FFPE) radical prostatectomy tumour tissues, amplified and hybridized to Human Exon 1.0 ST microarrays (Thermo Fisher). FOXA1 mutant transcriptional signature. By following the similar strategy as previously reported for SPOP mutants 13 , we developed the FOXA1 mutant transcriptional signature that includes 67 genes differentially expressed between FOXA1 mutant and wild-type samples from TCGA prostate cancer RNA-seq data. The low-expressed genes (mean RNA-seq by expectation maximization (RSEM) <1) were filtered before the analysis. Specifically, we identified significantly differentially expressed genes by comparing FOXA1 mutants within FKHD DNA-binding domain and wild-type cases as determined from DNA mutational analyses among TCGA samples lacking ETS family gene fusions (ERG, ETV1, ETV4 and FLI1), using Wilcoxon rank-sum test and controlled for false discovery using BenjaminiHochberg adjustment (FDR ≤ 0.05). SCaPT development based on FOXA1 mutant transcriptional signature and SVM model. To predict tumours in the FOXA1 mutant subclass in the absence of DNA sequencing data (that is, microarray datasets), we developed the subclass predictor based on transcriptional data (SCaPT) model based on the support vector machine (SVM) model. Given a set of training data marked with two categories, SVM builds a model that assigns testing data into one category or the other, making it a non-probabilistic binary linear classifier. In our SCaPT model, the training data were defined as the transcriptional scores of FOXA1 mutant signature from TCGA cohort. The testing data would be the transcriptional z scores from RNA-seq or microarray expression data of FOXA1 mutant signature. Prostate cancer molecular subclass prediction by decision tree. In each individual study of retrospective and prospective GRID cohorts, the FOXA1 mutant subclass was first predicted using the SCaPT model. Next, using a decision tree and previously developed microarray-based classifiers for the ERG + and ETS + subtypes, we classified the remaining cases in each cohort. Some cases with both predicted FOXA1 mutant and ERG + ETS + status were classified as conflict subclass, and the rest without FOXA1 mutant calling and outlier expression were considered as 'other' subclass. Statistical analysis of human data. Statistical analyses were performed in R v.3.4.0 (R Foundation). All statistical tests were two-sided with a significance level of P < 0.05. Univariate logistic regression analyses were performed on the combined cohort to test the statistical association between FOXA1 mutant status and clinical variables, including age, race, pre-operative prostate-specific antigen (PSA), Gleason score, lymph node invasion (LNI), surgical margin status (SMS), extracapsular extension (ECE) and seminal vesicle invasion (SVI). We evaluated the associations between FOXA1 mutant status and patient outcomes including biochemical recurrence (BCR), metastasis (MET) and prostate cancer specific mortality (PCSM) on the basis of Kaplan-Meier analysis. ATAC-seq. Freshly sorted cells carrying pCW constructs (dsRED + ) were seeded in triplicate per infected construct at the start of the assay, and moving forward, replicates were processed independently, collected at the appropriate time points. CRISPR cell lines carried LentiCRISPRv2 with either the control guide (sgNT), guide 14 for FOXA1 (sgFOXA1_1) or guide 15 for FOXA1 (sgFOXA1_2). At time of collection, cells were trypsinized, and 50,000 cells (counted by using trypan blue exclusion) were processed for ATAC-seq as follows. After a wash step in cold cell wash buffer (CWB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ), outer membranes were disrupted in lysis buffer (CWB + 0.1% NP40) for 2 min on ice. The lysis reaction was stopped with the addition of 1 ml CWB. After a centrifugation step at 1,500g for 10 min, pelleted nuclei were kept for the next step. In a 50-μl final volume, tagmentation was performed for 30 min at 37 °C, using the Nextera DNA library prep kit (Illumina FC-121-1030). After addition of SDS to 0.2% final concentration, DNA was purified on AMPure XP beads (Beckman Coulter A63881) using a 2:1 ratio (v/v) of beads:tagmented DNA. Freshly eluted DNA was barcoded and amplified in 110-μl PCR volume (NEB Next Q5 Hot Start HiFi PCR, M0543L) to generate a library with the following PCR program: 65 °C, 5 min; 98 °C, 30 s; 11 cycles of (98 °C, 10 s ramping to 65 °C, 30 s), 4 °C hold. Quality control of the libraries was performed with a Bioanalyzer 2200 (Agilent Technologies, D1000 screentapes and reagents, 5067-5582) to assess size range of amplified DNA fragments and with Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher P11496) to quantify the DNA fragments generated. ATAC libraries were then pooled at equimolar concentration and were sequenced multiplexed on the Illumina HiSeq with 50-bp paired-ends. ATAC-seq data and preprocessing. ATAC-seq data preprocessing was performed as previously described. Raw ATAC-seq reads were trimmed and filtered for quality using Trim Galore! v.0. to different chromosomes or that mapped too far away were discarded. Unpaired reads, discordant reads, reads with mapQ <20, or SAM flags 0x4 and 0x400, as well as reads marked as optical or PCR duplicates using picard MarkDuplicates v.2.18.3-SNAPSHOT and reads overlapping the ENCODE mm10 functional genomics regions blacklist (at mitra.stanford.edu/kundaje/akundaje/release/ blacklists/mm10-mouse/mm10.blacklist.bed.gz) were removed to improve the quality of the retained fragments. To correct for the fact that the Tn5 transposase binds as a dimer and inserts two adapters in the Tn5 tagmentation step, all positive-strand reads were shifted 4 bp downstream and all negative-strand reads were shifted 5 bp upstream to centre the reads on the transposase-binding event.
Overall mapping statistics confirmed high-quality ATAC-seq data, with a high alignment rate (over 76.8% in all samples) and high coverage (over 30 million aligned read pairs per sample) across experiments (Supplementary Table 13 ). As an additional quality control metric, we confirmed that all ATAC-seq libraries displayed the expected insert size distribution computed from aligned read pairs, with nucleosome-free, mono-nucleosomal, and di-nucleosomal modes (see Extended Data Fig. 8a for representative plots) . ATAC peak calling, reproducibility analysis and atlas creation. We then pooled the shifted reads by sample and identified peaks using MACS2 with a threshold of FDR-corrected P < 0.01 using the Benjamini-Hochberg procedure for multiplehypothesis correction. As called peaks may be caused by noise in the assay and not reflect true chromatin accessibility, we calculated an irreproducible discovery rate (IDR) for all pairs of replicates across a cell type. Given two ranked lists of events from replicate experiments, in this case peak calls ranked by P value, IDR estimates a threshold at which events are no longer reproducible. Using this measure, we excluded peaks that were not reproducible (IDR <0.005) in at least one pair of replicates for at least one cell type or time point.
Reproducible peaks from each cell type were combined to create a genome-wide atlas of accessible chromatin regions. Reproducible peaks from different samples were merged if they overlapped by more than 75%. This produced an atlas of ~182,800 reproducible peaks of median width 586 bp. The numbers of reproducible peaks per time point and organoid line are provided in Supplementary Table 14 . Track diagrams at specific loci visually confirm that replicate ATAC-seq experiments show reproducible accessible sites (Extended Data Fig. 8b) . Assignment of ATAC-seq peaks to genes. The RefSeq transcript annotations of the mm10 mouse genome were used to define the genomic location of transcription units. For genes with multiple gene models, the longest transcription unit was used for the gene locus definition. ATAC-seq peaks located in the body of the transcription unit, together with the 2-kb regions upstream of the transcription start site and downstream of the 3′ end, were assigned to the gene. If a peak was found in the overlap of the transcription units of two genes, one of the genes was chosen arbitrarily. Intergenic peaks were assigned to the gene with a transcription start site or 3′ end that was closest to the peak. In this way, each peak was unambiguously assigned to one gene. Peaks were annotated as promoter peaks if they were within 2 kb of a transcription start site. Non-promoter peaks were annotated as intergenic, intronic or exonic according to the relevant RefSeq transcript annotation. The atlas-wide distribution of promoter, intergenic or exonic peak assignment was consistent with high-quality ATAC-seq datasets (Extended Data Fig. 9) , with 31.6% of peaks at promoters and the rest nearly equally divided between intergenic and intronic regions, with a small fraction annotated as exonic. Differential peak accessibility. Reads aligning to the atlas peak regions were counted using htseq-count (-r pos s no). Differential accessibility of the peaks was assessed by applying DESeq2 v.1.18.1 to this count table, considering all pairwise comparisons of cell types. Peaks were defined as differentially accessible if they satisfied an FDR-corrected P < 0.05 and if the magnitude of the DESeq-normalized counts changed by a stringent factor of 4 or more between at least one pairwise comparison of organoid line to control (the comparisons used were EV day 1 vs FE255 day 1, EV day 1 vs R219 day 1, EV day 1 vs WT day 1, EV day 5 vs FE255 day 5, EV day 5 vs R219 day 5, EV day 5 vs WT day 5, WT day 1 vs FE255 day 1, WT day 1 vs R219 day 1, EV day 5 vs FE255 day 5, WT day 5 vs R219 day 5, sgNT day 5 vs sgFOXA1-sg1 day 5, and sgNT day 5 vs sgFOXA1-sg2 day 5) (two-sided Wald test, with Benjamini-Hochberg correction for multiple observations). MA plots for pairwise differential accessibility analyses confirmed that normalization was appropriate and that differential peaks displayed robust changes (see Extended Data Fig. 10 for representative plots and Supplementary Table 16 for numbers of differentially accessible peaks). These analyses produced a set of ~20,500 differentially accessible peaks of median width 410 bp; as expected, differential peaks were enriched for intergenic and intronic annotations and depleted for promoter annotations (Extended Data Fig. 9 ). ATAC-seq peak clustering. The ATAC-seq peak heat maps were created using the DESeq size-factor normalized read counts, applying the variance-stabilizing transformation to the full peak atlas, selecting the differentially accessible peaks, and then clustering using hierarchical clustering with the ward.D distance metric. Clusters were defined by cutting the hierarchical clustering at the first 8 bifurcations of the dendrogram by ward.D distance. The number of clusters was chosen to be eight based on observation of biologically interesting patterns of accessibility, and then peaks were sorted within each cluster by maximum signal. Peak heat maps. Heat maps (tornado plots) of peaks were generated by combining signals across replicates and binning the region ±750 bp around the peak summit in 1-bp bins after adjusting the reads for Tn5-induced bias, resulting in one signal track for each cell type or time point. Heat maps were generated using deeptools v.3.0.2. De novo transcription factor motif analysis. The Homer v.4.10 utility findMotifsGenome.pl was used to identify the top ten transcription factor motifs enriched in each of the clusters produced by deeptools from each time point relative to genomic background. The top motifs were reported and compared to the Homer database of known motifs and then manually curated to restrict to transcription factors that are expressed based on RNA-seq data and to group similar motifs from transcription factors belonging to the same family. FIMO motif search. Motif enrichment was performed relative to the 8 clusters defined by hierarchical clustering of 20,523 differentially accessible peaks (described above). Each ATAC-seq peak in the atlas was scanned for 718 transcription factor motifs in the Mus musculus CIS-BP database 42 using FIMO 43 of MEME suite 44 , using the default P value cut-off of 1 × 10
. The background sequence distribution for motif analysis was based on nucleotide frequencies in the full set of 20,523 differentially accessible peaks (A = T = 0.2711, C = G = 0.2289). Of the 718 motifs in the database, 713 had a match within at least one peak among the differentially accessible peaks. FIMO motif analysis. We restricted the analysis to 298 transcription factors that had a median RNA-seq expression across biological replicates of above 5 reads per kilobase of transcript per million mapped reads in at least one organoid line or time point. In addition, CTCF and CTCFL, DNA-binding proteins associated with 3D chromatin structure, were excluded. To rank the level of enrichment of transcription factor motifs in each cluster relative to the background, the number of peaks containing each motif was calculated for each cluster and for the full set of differentially accessible peaks. Enrichment-depletion scores for each motif in a cluster were reported as binomial Z-scores relative to the background of motif occurrences in the set of differential ATAC-seq peaks. Namely, if p represents the probability that a peak in the background set contains an occurrence of the motif, then the binomial Z-score for a cluster of size N with C peaks containing the motif is . While these Z-scores do not incorporate a correction for multiple hypotheses, in practice the top-ranked motifs have such strong enrichments that they would still be highly significant after correction. Non-canonical FOXA1 motif analysis. To examine enrichment-depletion of non-canonical FOXA1 motifs, we considered four additional motifs. First, we examined previously reported convergent and divergent FOXA1 dimer motifs. Second, we altered the canonical FOXA1 motif by replacing position 6 of the core GTAAAC/T pattern with either and equal probability of C/T (similar to canonical) or an equal probability of A/G (non-canonical). We used FIMO to search for hits of these motifs across differential peaks and reported enrichment-depletion within clusters as binomial Z-scores as before. ChIP-seq. Freshly sorted cells carrying pCW constructs (dsRED + ) were seeded in duplicate per infected construct at the start of the assay, and moving forward, replicates were processed independently, collected following five days of doxycycline treatment. At time of collection, cells were trypsinized and 70,000 cells (counted by using trypan blue exclusion) were processed for ChIP-seq as follows. Cells were fixed with formaldehyde (1%) and the reaction was quenched with glycine 1.25 M and Tris 1 M pH 8. Fixed cells were lysed with SDS lysis solution containing protease inhibitors. Re-suspended pellets were sonicated, precipitated with antibodies (HNF-3 alpha/FoxA1 antibody (3B3NB) (Novus Biologicals), AR (ER179(2), Abcam) and protein A/G bead complex. The chromatin and immune complex were sequentially washed with a low-salt solution, high-salt solution, LiCl solution and Tris-NaCl solution. Chromatin was eluted from the complex with a solution containing 1% of SDS and 0.1 M NaHCO 3 . Cross-linking between DNA and protein was reversed by adding NaCl solution and incubating at 65 °C overnight. Libraries were made using NEBNext Ultra II DNA library prep kit for Illumina (NEB E7645L). Quality control was performed with Bioanalyzer 2200 (Agilent Technologies, D1000 screentapes and reagents, 5067-5582) to assess size range of amplified DNA fragments, and with Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher P11496) to quantify the DNA fragments generated. ChIP libraries were then pooled at equimolar concentration and were sequenced multiplexed on the Illumina HiSeq with 50-bp paired-end sequencing. ChIP-seq normalization and analysis. To analyse ChIP-seq signal for AR and FOXA1 in each organoid line relative to ATAC-seq clusters, we normalized ChIP-seq data across experiments based on background signal, namely by defining flanking regions of reproducible peaks and using DEseq scaling factors relative to these regions for library size normalization. To compare AR or FOXA1 binding between a pair of organoid lines with respect to an ATAC-seq cluster, we compared the corresponding distributions of normalized ChIP-seq signal over peaks in the cluster by a one-sided Wilcoxon rank-sum test. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
The described RNA-seq, ATAC-seq and ChIP-seq data have been deposited in the Gene Expression Omnibus under the following accession numbers: GSE128667 (all data), GSE128421 (ATAC-seq sub-series), GSE128666 (RNA-seq subseries) and GSE128867 (ChIP-seq subseries). Patient predicted FOXA1 mutant status and outcome data from Decipher GRID are available from the authors upon reasonable request. 
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Extended Data Fig. 1 | Patients with predicted FOXA1 mutant status  have worse outcomes. a, Co-crystal structure of the FKHD domain of FOXA3 in complex with DNA resembling the FKHD consensus sequence (PDB 1VTN), with residues and folds of interest indicated, including α-helix 3 (orange), which sits in the major groove of DNA, and Wing2 (cyan), which undergoes frequent mutation in prostate cancer. b, Kaplan-Meier plot showing significantly different clinical outcomes of time to biochemical recurrence (BCR, top) or progression to metastatic disease (MET, bottom) for predicted FOXA1 mutant cases vs wild type in the GRID cohort. The difference of MET and BCR survival curves was tested with the R survdiff function, using the G-rho family of tests, without adjustments for multiple comparisons. RP, radical prostatectomy. c, Associations between predicted FOXA1 mutation status and clinical variables using univariate analysis of the GRID cohort, with FOXA1 wild type as reference. The GRID cohort included 1,626 radical prostatectomy tumour samples. The centre values represent the median odds ratio via univariate analysis. The error bars represent first and third quartiles of odds ratio. The lines represent minimum and maximum odds ratio. Univariate logistic regression analyses were performed on the GRID cohort to test the statistical association between FOXA1 mutant status and clinical variables via generalized linear test, without adjustments for multiple comparisons. The test was two-sided with the significance level of P < 0.05 as the cut-off. ADT, androgen deprivation therapy; PSA, prostatespecific antigen; RT, radiotherapy. Fig. 2 | Details of FOXA1 luciferase reporter assay. a, Schematic of FOXA1 luciferase reporter, depicting the modified response elements (at wobble positions within the canonical FOXA1 motif) cloned in tandem upstream of a minimal promoter driving luciferase expression. b, Dose-response curve of FOXA1 luciferase reporter activity in response to increased amounts of Foxa1 WT cDNA introduced into the system, expressed as a relative response ratio with 100% Foxa1
Extended Data
WT cDNA set to 1 and 0% Foxa1 WT cDNA (100% 'stuffer' DNA) set to 0. Data are from three biological replicates, central line and error bars represent mean ± standard deviation. c, Western blot of allelic series of FOXA1 mutants in HEK293T cells 24 h after transfection with equal amounts of cDNA as used in FOXA1 luciferase reporter assay. The ΔF254/E255 and ΔM253-N256 mutants are shown as F254_E255del and M253_N256del, respectively, in the Extended Data. CYCLO B, loading control cyclophilin B. Representative blot, experiment repeated three independent times with similar results. For source gel data, see Supplementary Fig. 1 . Fig. 3 | Inducible overexpression of FOXA1 variants  influences organoid lumen size and morphology. a, Schematic of doxycycline-inducible pCW-FOXA1 constructs used in the study. b, Western blot analysis of lysates from pCW-FOXA1(WT) organoids following acute doxycycline treatment. Representative blot, experiment repeated two independent times with similar results. For source gel data, see Supplementary Fig. 1 . c, Western blot analysis of lysates from organoids following long-term doxycycline treatment. Sizes of endogenous and Flag-tagged FOXA1 are noted, as well as the smaller truncated form from G275X at the expected size ~38 kDa. Representative blot, experiment repeated three independent times with similar results. For source gel data, see Supplementary Fig. 1. d Fig. 4 | Analysis of FOXA1 alterations in FOXA1-deleted or PTEN-deleted contexts. a, CRISPR-Cas9-mediated knockdown of Foxa1 results in a markedly altered morphology. Organoids lacking Foxa1 (sgFoxa1) have a reduced capacity to form lumens while maintaining expression of AR and the basal marker p63. sgNT (guide RNA targeting human gene AAVS1) serves as a negative control. b, Western blot analysis of lysates from organoids carrying control guide RNA (sgNT) or guide RNA targeting Foxa1. Representative blot, experiment repeated three times with similar results. For source gel data, see Supplementary  Fig. 1 . c, Quantification of organoids containing lumens, seven days after trypsinization in normal organoid media. Data are from three biological replicates, bars represent mean ± standard deviation, P value calculated using unpaired, two-tailed Student's t-test. d, Sequence indicating the location of three silent point mutations introduced upstream of the PAM sequence for Foxa1-targeting RNA sgFoxa1_1. e, Western blot analysis of lysates from organoids carrying either CRISPR-Zeo-sgGFP (CZsgGFP) or CRISPR-Zeo-sgFoxa1_1 (CZsgFoxa1) in addition to the pCW construct indicated, either EV or with a Foxa1 allele present, plus or minus doxycycline treatment for ten days. Representative blot, experiment repeated twice with similar results. For source gel data, see Supplementary Fig. 3a to quantify the reduction in AR binding following FOXA1 wild-type or mutant overexpression, and the increase in FOXA1 wild-type binding at those sites where AR is lost. Box: 25th to 75th percentile; band: median; top whisker: 75th percentile plus 1.5 times interquartile range; bottom whisker: 25th percentile minus 1.5 times interquartile range. Sample size = 2,914 peaks. P values calculated using an unpaired, one-sided Wilcoxon test. b, Western blot analysis of lysates from AR-deficient organoids generated using CRISPR-Cas9 carrying representative Foxa1 alleles. Levels are significantly reduced but AR is not completely absent (as seen on the long exposure); this is a bulk population rather than single cell clones and thus a small number of cells escaped CRISPR-Cas9-mediated Ar deletion. Cells were treated with doxycycline for at least ten days. Representative blot, experiment repeated twice with similar results. For source gel data, see Supplementary Fig. 1 . c, Expression of mouse orthologues of AR-target genes found in the AR signature used in TCGA cohort analysis based on mouse organoid RNA-seq. Genes depicted are those that have a mouse orthologue of the human gene found in the signature, and a significant expression change (DESeq2 adjusted P < 0.05) compared to EV control at 11 days of doxycycline treatment, as well as Psca, an AR-target gene expressed in mouse organoids. Data are from RNA-seq of three biological replicates. FE, F254_E255del. d, FOXA1(F254_E255del) signature can predict mutant tumours in TCGA. Hierarchical clustering and heat map of significantly differentially expressed genes between mouse FOXA1(F254_E255del) organoids and EV control (FDR ≤ 1 × 10 −10 ). Human homologues of differentially expressed genes (DEGs) from this analysis were used to cluster FOXA1 mutant tumours (n = 14) and can detect nearly all FOXA1 mutant human tumours (P = 2.1 × 10 −8 ) out of the 333 TCGA samples, 199 of which are ETS + . Two-sided Fisher's exact test was used to test the enrichment of FOXA1 mutant samples within each sub-cluster, without adjustments for multiple comparisons. Fig. 6 | Integrated analysis of ChIP-seq, ATAC-seq and RNA-seq data in FOXA1 mutant organoid lines. a, Cluster 0 peaks have higher FOXA1 ChIP-seq signal in F254_E255del mutant organoid than empty vector control. Box plots show normalized day five AR ChIP-seq signal and FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 0, where normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly higher in F254_E255del (FE) and in WT compared to EV control (P values are listed in Supplementary  Table 11 ). Sample size = 5,260 peaks. b, Cluster 1 peaks have higher FOXA1 ChIP-seq signal and lower AR ChIP-seq signal in FOXA1(WT)-overexpressing organoids than in EV control. Box plots show normalized day five AR ChIP-seq signal and FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 1, where normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly higher, and AR ChIP signal significantly lower, in WT compared to EV control. Sample size = 1,493 peaks. c, Cluster 3 peaks have higher FOXA1 ChIPseq signal in R219S organoid than EV control. Box plots show normalized day five AR ChIP-seq signal and FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 3, where normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly higher in R219S compared to EV control. Sample size = 6,641 peaks. d, Cluster 5 peaks have higher FOXA1 ChIP-seq signal and lower AR ChIP-seq signal in R219S organoid than EV control. Box plots show normalized day five AR ChIP-seq signal and FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 5, where normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly higher, and AR ChIP signal significantly lower, in R219S compared to EV control. Sample size = 1,983 peaks. In a-d, box: 25th to 75th percentile; band: median; top whisker: 75th percentile plus 1.5 times interquartile range; bottom whisker: 25th percentile minus 1.5 times interquartile range. P values calculated using an unpaired, one-sided Wilcoxon test. e, Genes associated with cluster 0 are significantly induced in F254_E255del mutant organoids. Top, plots show empirical cumulative distribution of log 2 expression changes at 24 h vs day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) organoids for all expressed genes (black), genes associated with at least one ATAC-seq peak in cluster 0 (cluster 0-associated genes, red), and the top quartile of these genes based on number of assigned cluster 0 peaks (strong cluster 0-associated genes, yellow). Cluster 0-associated genes show strong expression induction compared to all genes in F254_E255del as well as in WT (red vs black) but not in R219. Bottom, As a control, similar cumulative log 2 expression changes for cluster 1-associated genes (red) or strong cluster 1-associated genes (yellow) do not show significant induction in F254_E255del. All P values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank-sum tests. f, Genes associated with cluster 0 are significantly induced in F254-E255del mutant organoids. Top, plots show empirical cumulative distribution of log 2 expression changes at 11 days vs day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) organoids for all expressed genes (black), genes associated with at least one ATAC-seq peak in cluster 0 (cluster 0-associated genes, red), and the top quartile of these genes based on number of assigned cluster 0 peaks (strong cluster 0-associated genes, yellow). Cluster 0-associated genes show strong expression induction compared to all genes in F254_E255del as well as in WT but not in R219. Bottom, As a control, similar cumulative log 2 expression changes for cluster 1-associated genes (red) or strong cluster 1-associated genes (yellow) do not show significant induction in F254_E255del. All P values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank-sum tests. g, Genes associated with clusters 3 and 5 are significantly induced in R219S mutant organoid. Top, plots show empirical cumulative distribution of log 2 expression changes at 24 h vs day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) organoids for all expressed genes (black), genes associated with at least one ATAC-seq peak in cluster 3 (cluster 3-associated genes, red), and the top quartile of these genes based on number of assigned cluster 0 peaks (strong cluster 3-associated genes, yellow). Cluster 3-associated genes show strong expression induction compared to all genes in R219S but not in WT or F254_E255del. Bottom, similar analysis for cumulative log 2 expression changes for cluster 5-associated genes (red) and strong cluster 5-associated genes (yellow). These genes are significantly induced in R219S and repressed in F254_E255del in WT for this time point. All P values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank-sum tests. h, Genes associated with clusters 3 and 5 are significantly induced in R219S mutant organoid. Top, Plots show empirical cumulative distribution of log 2 expression changes at day 11 vs day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) organoids for all expressed genes (black), genes associated with at least one ATAC-seq peak in cluster 3 (cluster 3-associated genes, red), and the top quartile of these genes based on number of assigned cluster 0 peaks (strong cluster 3-associated genes, yellow). Cluster 3-associated genes show strong expression induction compared to all genes in R219S but not in WT or F254_E255del. Bottom, similar analysis for cumulative log 2 expression changes for cluster 5-associated genes (red) and strong cluster 5-associated genes (yellow). These genes are significantly induced in R219S and repressed in F254_E255del. All P values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank-sum tests. Fig. 10 | MA plots for differential accessibility analysis. a, MA plots for differential accessibility analysis relative to EV controls. Representative MA plots (log (fold change) vs mean read counts) for differential peak accessibility analysis of FOXA1 mutant-and WTexpressing organoid lines vs empty vector controls at day 0, day 1, and day 5. Peaks that are significantly differential at FDR-corrected P < 0.05 are shown in colour. Dotted lines at log (fold change) = 2 and log (fold change) = −2 show cut-offs used for requiring robust accessibility changes in pairwise comparisons. b, MA plots for differential accessibility analysis at different time points relative to day 0. Representative MA plots (log (fold change) vs mean read counts) for differential peak accessibility analysis in each organoid line at day 1 vs day 0 and day 5 vs day 0. In a, b, all sample sizes are n = 183,093 (number of peaks in the atlas). Peaks that are significantly differential at FDR-corrected P < 0.05 are shown in colour, using two-sided Wald test with Benjamini-Hochberg correction. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
, Quantification of lumen areas measured at ten days after seeding. Solid black bar represents geometric mean. Values for sample size (indicated as dots) and P values are as follows: EV (292), +WT (284, P < 0.0001 over EV), +R219S (60, <0.0001), +F254_E255del
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The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
See methods "RNA isolation and sequencing", "Assay for Transposase Accessible chromatin (ATAC) coupled with Next Generation Sequencing (NGS)" and "Chromatin Immuno-Precipitation (ChIP) coupled with Next Generation Sequencing (NGS)" Specific software includes Nikon NIS elements software.
Data analysis
See methods, "ATAC data and preprocessing", "ATAC-seq atlas creation", "Assignment of ATAC-seq peaks to genes", "SCaPT development based on FOXA1 mutant transcriptional signature and SVM model" and "Prostate cancer molecular subclass prediction by decision tree" and "Bio-informatics analysis ChIP-seq." Specific software includes: STARaligner (v2. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability All data will be made available from the authors upon reasonable request. The described RNA-seq and ChIP-seq and ATAC-seq data will be deposited in the Gene Expression Omnibus in the future.
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Sample size
No sample size calculation was done, for most assays, 3 biological replicates were carried out. For organoid lines, there are often more than 3 because lines were often included in a replicate experiment before results of previous experiment was analyzed, resulting in a greater number of replicates than what was likely needed.
Data exclusions Entire growth assays were excluded if the control line did not grow as expected (i.e. didn't recover well from sorting so there was no growth seen). In that situation, data from entire experiment (all lines) were excluded. Mouse tumor measurements were excluded from data if it was noted at the time of injection that there was a technical issue. Both of these circumstances were pre-established and were held true for all lines.
Replication
All findings were reproducible, as more than 1 biological replicate was generally carried out, or the sample sizes were large enough to ensure good representation of the population behavior.
Randomization No randomization was done for our experiments because there were no drug treatment groups, and all work was done in vitro.
Blinding
For lumen size assays, actual measurements were carried out by a member of the lab who did not have any knowledge of which alleles were associated with growth/lumen formation phenotypes. All other experiments were not blinded and it was not necessary to be as they were much more quantitative and less subjective.
Reporting for specific materials, systems and methods Primary mouse organoid lines were established in our laboratory for this study Authentication since these were developed in our lab, authentication was not necessary
Mycoplasma contamination
All organoid lines used were tested for mycoplasma contamination and were found to be negative Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission
Provide a list of all files available in the database submission.
Genome browser session (e.g. UCSC)
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.
Methodology Replicates
Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.
Antibodies
HNF-3 alpha/FoxA1 Antibody (3B3NB) (Novus Biologicals), AR (ER179(2), Abcam)
